Clinical Trial Update: Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial of squalamine lactate ophthalmic solution (0.2%) for neovascular age-related macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Squalamine lactate ophthalmic solution 0.2% (squalamine lactate ophthalmic solution)

Snippet

Sponsor: Ohr Pharmaceutical Inc. | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: WITHDRAWN